Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool March 16, 2006 Rich Smith	Dueling Fools: Dell Bull Rebuttal Dell's so good, so efficient, and so well known that its reputation and brand name enable it to sell computers at higher prices than others can charge. Dell shareholders then reap the benefits of that pricing power.
The Motley Fool October 6, 2004 Bill Mann	Exit Blog, Enter Legg A high-profile Blogger's departure and a higher-profile stock purchase by Legg Mason Value Trust mean nothing ever gets boring at Google.
The Motley Fool July 18, 2011 Brian Orelli	A $3.6 Billion Franchise at Stake Amgen and Teva settle their patent dispute, and Amgen investors have a little better idea of when the company's $3.6 billion Neupogen and Neulasta franchise might come under attack in the United States.
The Motley Fool January 15, 2008 Brian Orelli	Fewer Generics in Fido's Future TEVA considers selling its small animal-health business.
The Motley Fool June 4, 2007 John Reeves	Insights From America's Greatest Money Manager Do you have the patience to earn outstanding returns?
The Motley Fool March 16, 2006 Rich Smith	Dueling Fools: Dell Bull Dell is currently selling for 20 times trailing earnings and fewer than 17 times trailing free cash flow. Its profits are projected to grow 15% per annum over the next five years. Is that a bargain? No. But it is a good price.
The Motley Fool December 2, 2005 Stephen D. Simpson	Quite a Quarter for OmniVision There's no denying recent gains, but can the specialty semiconductor company continue to reward faithful shareholders?
InternetNews December 5, 2007	Dell Vows to Fight Decline With $10B Stock Buyback A massive repurchase plan aims to regain value as Dell faces greater competition from Acer, Lenovo and market leader HP.
The Motley Fool November 2, 2009 Rick Aristotle Munarriz	Not So Fast, Bill Miller Unless something catastrophic happens to Legg Mason funds during the last two months of 2009, the legendary fund manager will be back to beating the market.
The Motley Fool August 17, 2011 Anders Bylund	Dude, Dell Is Getting the Hint The computer cowboy is a radically different company these days.
The Motley Fool May 3, 2011 Brian Orelli	Teva's Branded-Drug Binge For a company that's a generic-drug maker, Teva Pharmaceuticals sure does like its branded drugs. Despite the warts the company is ponying up $6.2 billion to buy Cephalon.
The Motley Fool February 12, 2007 Nathan Slaughter	I Love Bill Miller Perhaps more than any other investor over the past decade, the famed Legg Mason money manager has helped discredit the efficient market hypothesis and carry the banner for active fund management.
The Motley Fool March 5, 2008 Brian Orelli	Teva Wants the FDA to Do What? Teva wants the FDA to reinstate another drugmaker's patent.
The Motley Fool September 15, 2006 Tim Beyers	Look Who's Buying Dell! But why do investors like this stock? Here's a reader sample.
The Motley Fool September 22, 2009 Robert Steyer	Will Teva Be Forced to Take Its Own Medicine? Teva's biggest source of revenue and profit, the multiple sclerosis drug Copaxone, is facing a patent challenge.
The Motley Fool November 20, 2010 Anders Bylund	Dell Still Doesn't Get What Consumers Want Here's how you can unlock some value from that loser division, Mike.
InternetNews February 19, 2010	Dell's Results Gets a Mixed Vote From Analysts Despite good numbers, growth and an optimistic conference call, the stock suffered and analyst opinions are all over the board.
The Motley Fool July 30, 2008 Brian Orelli	Teva Has Revenue in All the Wrong Places Sometimes double-digit growth isn't all it's cracked up to be. For generic-drug maker Teva Pharmaceuticals, the growth wasn't quite as exciting as the company's top line might suggest.
The Motley Fool May 22, 2006 Seth Jayson	Dell's Still a Dog Dell's not cheap enough for wise investors. Here's why.
The Motley Fool May 15, 2008 Brian Orelli	Wanted: FDA Approval -- Pronto Teva and Amphastar have the courts on their side, but the FDA still stands in the way of a generic-drug launch.
The Motley Fool November 3, 2010 Brian Orelli	Teva's New Drugs Pay Off The generic-drug maker keeps generating big profits.
The Motley Fool August 25, 2006 Warren Gump	Warning Flags That Should Slow Down Investors The biggest mistake typical of the value investor is buying a stock too early and experiencing a precipitous fall before an ultimate rebound.
The Motley Fool February 1, 2006 David Meier	Don't Screw Up Want to maximize your investing power? Make the right kind of mistakes. Here's a value investor's approach to minimizing errors.
The Motley Fool May 7, 2008 Brian Orelli	Teva's on a Tear The generic-drug maker can't be stopped.
The Motley Fool March 3, 2004 Alyce Lomax	Biovail Gets Nailed... Again The Canadian drug maker's stock falls on downbeat guidance.
The Motley Fool August 2, 2010 Jordan DiPietro	This Is How Bill Miller Crushes the Market Invest like Bill Miller and look for tech stocks with great value.
The Motley Fool November 26, 2008 Brian Orelli	Watson Gets Some Hand-Me-Downs Much like discount stores, generic-drug makers are in a cutthroat low-margin business, where "larger" almost always means "better."
The Motley Fool March 19, 2009 Brian Orelli	Teva: An Equal-Opportunity Bully Making money by picking on the little guy, too.
The Motley Fool April 25, 2011 Sean Williams	Pharma's Most Impervious Pipeline An investment in generics doesn't have to be a bad thing.
The Motley Fool September 9, 2010 Jim Mueller	Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker.
The Motley Fool February 15, 2005 Stephen D. Simpson	Teva: Scourge of the Drug World? The world's largest generics maker continues to post strong growth by bedeviling Big Pharma.
The Motley Fool May 9, 2006 Seth Jayson	Dell Is Dead to Me Dell is currently priced for zero or negative growth for a long time. Investors, there is no good reason to bet hard-earned dollars that the company can turn things around.
The Motley Fool February 17, 2010 Brian Orelli	This Is Not Your Generic Cash Production Teva's generating cash and knows how to use it.
The Motley Fool September 25, 2008 Brian Orelli	Teva Heads to Japan It's conquering the world, slowly but surely. But is it still a value play?
The Motley Fool July 28, 2009 Brian Orelli	All Growth, All the Time This generic-drug maker is no value play.
PC Magazine January 12, 2005 Sebastian Rupley	Big Blue Sells PC Unit Lenovo will take over, but PCs will stay IBM-branded for some time.
The Motley Fool May 2, 2006 Alyce Lomax	Dell Digs for Customers Reports of serious bargains from Dell may make some investors a wee bit nervous.
The Motley Fool May 30, 2006 Tim Beyers	Better Know a Fund Manager Up this week: Bill Miller and Legg Mason Value Trust. Is this fund for you?
The Motley Fool August 18, 2006 Nathan Parmelee	All's Not Swell at Dell It's tough for investors to find reasons for optimism with this computer maker.
The Motley Fool January 6, 2009 Rick Aristotle Munarriz	The Worst Mutual Funds of 2008 Bill Miller is the yardstick in another bad year for Legg Mason.
The Motley Fool June 1, 2006 Rich Smith	Will Dollar General Show Investors the Money? Is this discount retailer a value or a value trap? Investors, take note.
The Motley Fool March 4, 2009 Tim Beyers	Is Dell Doomed? Nope. Despite some bad revenue numbers Dell produced $690 million in free cash flow last quarter.
The Motley Fool February 17, 2011 Anders Bylund	What Dell Learned From "Office Space" The computer maker deserved this pop.
The Motley Fool November 1, 2005 Stephen D. Simpson	Belly Up to Barr Though not cheap, this is a high-quality generic drug company. However, investors must do their own due diligence and decide for themselves whether today's price offers enough margin of safety for a sound investment.
The Motley Fool November 8, 2005 Stephen D. Simpson	Teva Is No Generic Generics Firm Although 2005 wasn't a great year for generics on the whole, 2006 is shaping up to be pretty interesting for Teva. Is it time to buy these shares?
BusinessWeek December 20, 2004 Steve Hamm	Big Blue's Bold Step Into China It doesn't take a genius to see why IBM's sale of its $10 billion-a-year PC business to China's Lenovo Group Ltd. relieves a huge headache for Big Blue. Teaming with Lenovo spells opportunity -- if it can meet the big challenges ahead.
The Motley Fool November 17, 2011 Amanda B. Kish	Bill Miller Heads for the Exit The legendary investor is throwing in the towel. What lessons have we learned?
The Motley Fool November 30, 2007 Anders Bylund	Hey, Mr. Market! Dell Deserves Better! Dell is down following earnings reports, but for all the wrong reasons. Maybe it's time to buy.
The Motley Fool October 28, 2009 Chris Jones	Bill Miller Thinks Outside the Box Legg Mason fund guru Bill Miller is bucking the pessimistic crowd, arguing that fleeing from equities could prove to be a bad move.
The Motley Fool November 30, 2007 Rich Duprey	Bill Miller's New Streak After an amazing 15-year run of beating the S&P 500 index, legendary value investor Bill Miller and his Legg Mason Value Trust are shaping up to fall short of the benchmark for the second year in a row. Has the guru lost his mojo?